+1 (202) 780-3397
Androgen receptor expression in triple negative and non-triple negative and its relation to clinical, Pathological and ethical features
19th International Conference on CANCER AND CANCER THERAPY
December 07, 2022 | Dubai, UAE
Jamal Zidan
Bar-Ilan University, Israel
Scientific Tracks Abstracts : J Can Clinical Res
Abstract:
Background: Breast cancer is the most common tumor among women. It constitutes 33% of all tumors in women in Israel. In addition to stage of the disease, other detective factors such as Estrogen receptors (ER) and Progesterone receptors (PR), Human epidermal growth factor receptor 2 (HER2) and proliferation index (KI67) are examined to determine the treatment for metastatic disease and for the adjuvant therapy. Despite a good prognosis of breast cancer about 10-15% of breast tumors do not contain ER, PR, HER2. This group of is more, aggressive, called Triple negative (TN) tumor. In TN tumors the treatment is mainly chemical therapy, and the survival is lower than other types (Non triple negative: NTN) of breast cancers. Androgen receptor (AR) receptor is very important in prostate cancer and forms the basis of hormonal treatments for prostate cancer. AR can also be present in some breast cancer patients. This study examined AR levels in patients with TN breast cancer in order to evaluate whether AR could be used as a prognostic or therapeutic factor in patients with TN breast cancer Methods: Demographic, clinical and pathological data were collected from the files of breast cancer patients treated at the Oncology Institute at Ziv Medical Center, Israel, between 2013 and 2020. Tissue samples were taken from the tumors at the Ziv Pathological Institute which were stored in paraffin. The evaluation of AR in breast cancer tissues was done by immunohistochemistry test. 55 TN cases were examined along in addition 90 cases with NTN were examined for comparison. Results: The mean age of the patients in the TN group was 56.9 ± 16.2 compared with 59.8 ± 13.5 years in the NTN group. 83.6% were Jewish and 16.4% Arab. 36.4% of TN patients were of childbearing age. 61.8% of the tumors in TN were Grade 3 compared to 32.2% in the NTN group (P = 0.001). Ki67) was 57.4 ± 27.8 in TN tumors and 24.9 ± 25.4 in NTN (0.001
Biography:
Jamal Zidan earned his Doctorate in Medicine (MD) at the Semmelweis University in Budapest, Hungary. He has finished his specialization in Oncology at the Oncology department at Rambam Medical Center in Haifa, Israel. Since 2006 he was Associat Professor at the Faculty of Medicine at the Technion University in Haifa, Israel. At 2009 he was a Visiting Scientist in Biological Regulation Department in Weizmann Institute of Science, Rehovot. Israel. Since October 2011 he is a professor at the Faculty of Medicine in the Galilee, Safed, Bar-Ilan University, Israel, and since June 2013 he is Full Professor of Medicine.
PDF HTML